ImmunoTargets and Therapy (Oct 2023)

Globoid Cell Leukodystrophy (Krabbe Disease): An Update

  • Maghazachi AA

Journal volume & issue
Vol. Volume 12
pp. 105 – 111

Abstract

Read online

Azzam A Maghazachi Research Department, ImmnoProfiling and Boosting, Oslo, NorwayCorrespondence: Azzam A Maghazachi, Research Department, ImmunoProfiling and Boosting (IPAB), Oslo, Norway, Email [email protected]: Globoid cell leukodystrophy or Krabbe is a disease that affects children as well as adults who have mutations in the gene encoding the enzyme galactosylceramidase/galctocerebrosidase (GALC), resulting in the deposition of the toxic lipid D-galactosyl-beta1-1’ sphingosine (GalSph or psychosine). Several therapeutic modalities were used to treat patients with Krabbe disease, including hematopoietic stem cell transplantation, enzyme replacement therapy, autophagy activators, intravenous immunoglobulin, and inhibitors of the Pyroptosis process, among many other approaches. In this article, I will briefly discuss the disease in both human and animal model, describe recent clinical observations as well as methods utilizing genetic analysis for diagnosis, and finally review recent advances in treating this rare and devastating disease.Keywords: Krabbe disease, globoid cell leukodystrophy, twitcher mice, GALC, treatment, diagnosis, genetics, cancer

Keywords